One of the largest-ever studies on the topic of deprescribing medications shows the potential promise, and pitfalls, of a massive effort to reduce overuse of a common class of heartburn medications known as proton pump inhibitors or PPIs. It also reveals that some of the feared risks from PPIs may be overblown.
